Effect of @entity3988 on cardiac function assessed by echocardiography and neurohumoral factors after reperfused @entity583 without XXXX .

@entity1 @entity712 @entity1425 @entity3876 @entity3988 @entity583 @entity1063
The purpose of this study was to examine the effect of @entity3988 on cardiac function and neurohumoral factors ( @entity3876 , @entity1425 , @entity1063 ) after reperfused @entity583 without @entity712 (Killip class I). On the first day after @entity583 following reperfusion therapy @entity1 were randomly assigned to @entity3988 treatment (group 1, n=33) or no treatment (group 2, n=39). We then performed echocardiographic examinations on the @entity1 and measured heart rate, mean blood pressure and neurohormones ( @entity3876 , @entity1425 and @entity1063 ). Follow-up evaluations of echocardiography were performed at 4 and 12 weeks and of neurohormones at 1 and 4 weeks after @entity583 . The highest peaks of plasma @entity3876 , @entity1425 , and @entity1063 levels were observed before treatment and decreased with time in both groups. After 4 weeks the level of plasma @entity3876 in the @entity3988 treatment group was lower than in the no treatment group [55+/-3 pg/mL vs 85+/-5 pg/mL (P < 0.05)]. Other neurohormones did not differ between groups. Fractional shortening (FS) and ejection fraction (EF)improved after @entity583 in both groups, but significantly more in the @entity3988 group (P < 0.05) after 12 weeks of treatment. Changes in @entity3876 correlated significantly with changes in left ventricular end systolic volumes, FS and EF. In this study, @entity3988 significantly improved systolic function and reduced the level of plasma @entity3876 after @entity583 , which suggest that @entity3988 may have a beneficial effect on @entity583 without @entity712 .
